

SPECIFIC BINDING OF LEUKOTRIENE B<sub>4</sub>  
TO GUINEA PIG LUNG MEMBRANES

Maan Saad and Kenneth Wong

Departments of Medicine and Pharmacology,  
University of Alberta, Edmonton, Alberta T6G 2G3 Canada

Received January 14, 1987

**Summary:** We have demonstrated binding sites for LTB<sub>4</sub> in guinea pig lung membranes. Binding of [<sup>3</sup>H]-LTB<sub>4</sub> was of high affinity (K<sub>d</sub> = 0.76 nM), saturable and linear with protein concentration (0.2 - 1.2 mg/ml). Scatchard and Hill's plot analysis indicated a single class of binding site with a Hill's coefficient of 0.99 ± 0.08 (n=4). [<sup>3</sup>H]-LTB<sub>4</sub> was unmetabolized during incubation with membrane preparations, as indicated by high performance liquid chromatography. Divalent cations such as Mg<sup>2+</sup> and Ca<sup>2+</sup> enhanced binding capacity without changing the K<sub>d</sub>. Na<sup>+</sup> ions decreased binding in a concentration-dependent manner. Guanine nucleotides, GTP, GTPγS and Gpp(NH)p also decreased the number of binding sites. Finally, competition experiments demonstrated the following order of potency for displacement of [<sup>3</sup>H]-LTB<sub>4</sub> from its receptor site: LTB<sub>4</sub> > 20-OH-LTB<sub>4</sub> >> 20-COOH-LTB<sub>4</sub> = 6-trans-12-epi-LTB<sub>4</sub> > LTC<sub>4</sub> = LTD<sub>4</sub> = 5-HETE. These data indicate that a specific LTB<sub>4</sub> receptor, in addition to the previously documented LTC<sub>4</sub> and LTD<sub>4</sub> receptors, exists in guinea pig lung. © 1987 Academic Press Inc.

Leukotriene (LT) B<sub>4</sub> [5(S), 12(R)-dihydroxy-eicosa-6,14-cis-8,10-trans-tetraenoic acid], is a product of the lipoxygenase pathway of arachidonic acid (AA) metabolism(1-3). LTB<sub>4</sub> production has been shown to occur in rabbit neutrophils (2), human neutrophils (4), human lung (5), and guinea pig lung (6). On a molar basis, LTB<sub>4</sub> is the most potent chemotaxin factor for human, rabbit and rat neutrophils (7-10). LTB<sub>4</sub> also induces neutrophil aggregation, generation of superoxide and degranulation in the presence of cytochalasin B (7-10). Another important action of LTB<sub>4</sub> is its ability to contract guinea pig

**ABBREVIATIONS:** LT - Leukotriene, 5-HETE - 5-Hydroxy Eicosatetraenoic Acid, AA - Arachidonic Acid, HPLC - High Performance Liquid Chromatography, K<sub>d</sub> - Dissociation Constant.

lung parenchymal strips and human isolated airways (11). In this regard,  $\text{LTB}_4$  is 100-1000 times more potent than histamine on a molar basis; however, it is less potent than the peptidoleukotrienes  $\text{LTC}_4$  and  $\text{LTD}_4$ . Binding studies have demonstrated that receptor sites for  $\text{LTB}_4$  occur on the extracellular side of human neutrophil membranes (12-14) and that receptors for  $\text{LTC}_4$  and  $\text{LTD}_4$  exist on human and guinea pig lung membranes (15-17). A noticeable absence of  $\text{LTB}_4$  binding data in lung tissue is apparent. In this communication we have documented receptor sites for  $\text{LTB}_4$  on guinea pig lung tissue and have studied some of the biochemical mechanisms regulating this specific receptor site.

#### MATERIALS AND METHODS

**Materials:**  $[14,15\text{-}^3\text{H(N)}]$ -leukotriene  $\text{B}_4$  (32 Ci/mmole) was purchased from New England Nuclear.  $\text{LTC}_4$ ,  $\text{LTD}_4$ ,  $\text{LTB}_4$ , 20-OH- $\text{LTB}_4$ , 20-COOH- $\text{LTB}_4$ , 5-HETE, and 6-trans-12-epi- $\text{LTB}_4$  were generous gifts from Dr. J. Rokach, Merck-Frosst, Inc., Point Claire-Dorval, Quebec. Unlabelled drugs were stored in aliquots at  $-70^\circ\text{C}$  until day of use. Dilutions were made with water and used within 2 days. Purity was regularly checked by HPLC. Guanosine  $5'-(3\text{-O-thio})$  triphosphate (GTP $\gamma\text{S}$ ), guanosine triphosphate (GTP) and guanylyl- $5'-(\beta,\gamma,\text{imino})$  triphosphate (Gpp(NH)p) were purchased from Calbiochem-Behring (San Diego, CA). All other chemicals and reagents used were of analytical grade.

**Preparation of Lung Membranes:** Lungs from freshly stunned and exsanguinated guinea pigs (Male, 300 g, English short-hair, Connaught Laboratories, Toronto, ON) were chopped into cubes 2 x 2 x 2 mm, in 10 volumes of homogenization buffer of the following composition: Tris-HCl and Tris base 10 mM (pH 7.0 at  $4^\circ\text{C}$ ), Ethylenediaminetetracetic acid (EDTA) (10 mM), phenylmethylsulphonyl fluoride (PMSF) (200  $\mu\text{M}$ ), Dithiothreitol, (1mM) and Sucrose (0.25M). The lung fragments were then disrupted using a polytron homogenizer at a setting of 6 for 30 seconds. The homogenate was centrifuged at 1000 g for 10 minutes to pellet unbroken chunks of tissue, nuclei and undrupted cells. After filtration through a layer of gauze, the supernatant was centrifuged at 110,000 g for 30 minutes. The pellet was re-suspended in the above buffer prepared without EDTA and PMSF. The suspended pellet was re-centrifuged two more times at 110,000 g for 30 minutes each. The final pellet was then suspended to a protein concentration of 3 - 4 mg/ml and stored in aliquots under liquid nitrogen until the day of use. Protein was determined by the method of Lowry (18) using bovine serum albumin as standard.

**$[^3\text{H}]\text{-LTB}_4$  Binding Assay:** All incubations were carried out in duplicate in micro-centrifuge tubes (capacity 1.5 ml). Total

assay volume was 250  $\mu$ l except in time course assays where the volume was scaled up appropriately (10-20 fold). In this case, clean scintillation vials were used. Drugs, Tris buffer 50 mM (pH 7.0), and [ $^3$ H]-LTB $_4$  were added and protein was used to start the reaction. Non specific binding was measured in duplicate tubes containing unlabelled LTB $_4$  (1.0  $\mu$ M). Specific binding was defined as the difference between total and nonspecific binding. The latter component was approximately 10-25% in all experiments. Tubes were vortexed to ensure the protein was suspended adequately. Binding was carried out at 25°C unless otherwise stated. Separation of the bound from free ligand was carried out by vacuum filtration through 25 mm Whatman GF/B filters and rapid washing with 3, 5 ml ice cold aliquots of Tris buffer 10 mM (pH 7.0). Dried filters were added to scintillation vials with 10 ml of liquid scintillant and the radioactivity counted in a scintillation counter at approximately 45% efficiency with quench correction. Data was analyzed by a computer program. Saturation analysis was aided by computer fitting of curves by the method of least squares. All data presented are the mean of duplicates and is representative of at least two other experiments performed on different membrane preparations.

## RESULTS AND DISCUSSION

[ $^3$ H]-LTB $_4$  binding to lung membrane was found to be saturable and of high affinity (figure 1). Initial studies showed that at 25° binding was optimal at pH 7.0, dependent on protein concentration and attained equilibrium after 10 min. Scatchard plots (figure 1, inset A) indicate a single class of binding sites with a Kd of  $0.76 \pm 0.04$  nM (n=3), and a binding capacity ( $B_{\max}$ ) of  $254 \pm 21$  fmoles/ $\mu$ g protein (n=3) for incubations carried out in the presence of 10 mM Ca $^{2+}$ . Hill's analysis of the data (inset B) yielded a Hill's coefficient of  $0.99 \pm 0.1$  (n=4) thus reinforcing the absence of cooperative interactions between receptors. The observed Kd value for LTB $_4$  binding in lung is similar to observed Kd values for LTB $_4$  binding to neutrophils (Kd = 0.46 nM, ref. 13) and for LTC $_4$  and LTD $_4$  binding to specific receptors in lung tissue (15-17).

HPLC analysis of [ $^3$ H]-LTB $_4$  recovered and isolated after incubation with membrane protein indicated that previously bound [ $^3$ H]-LTB $_4$  was chemically unchanged; in followup experiments the recycled ligand was able to bind lung membranes in a fashion




Figure 1. Saturation analysis of  $[^3\text{H}]\text{-LTB}_4$  binding to lung membranes, lung membranes (0.36 mg/ml) were incubated with increasing concentrations of  $[^3\text{H}]\text{-LTB}_4$  in the presence of  $\text{Ca}^{2+}$  (10 mM) at  $25^\circ\text{C}$  for 30 minutes. Similar tubes contained  $\text{LTB}_4$  (1  $\mu\text{M}$ ) to determine the nonspecific binding component. Curves were fitted by the method of least squares. Scatchard analysis of the data is shown in inset A. Hill plot analysis is shown in inset B.

identical to pure  $[^3\text{H}]\text{-LTB}_4$  (data not shown). It appears that during the binding process,  $[^3\text{H}]\text{-LTB}_4$  is not metabolized to a significant extent by lung tissue. These findings agree with other studies (19,20) which show that rat, human adult and human fetal lung do not metabolize  $\text{LTB}_4$  to its 20-hydroxy or 20-carboxy derivatives.

Figure 2 shows that in incubations carried out with membranes prepared in the presence of 10 mM EDTA, divalent cations ( $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ) increased the level of specific binding.  $\text{Ca}^{2+}$  was the most effective and at 10 mM increased the binding capacity by 37% ( $n = 3$ ) but did not alter the  $K_d$ . Monovalent cations,  $\text{Na}^+$ ,  $\text{Li}^+$ , and  $\text{K}^+$  reduced specific binding of  $[^3\text{H}]\text{-LTB}_4$  (figure 2B). The most effective cation, 1 M  $\text{Na}^+$ ,




Figure 2. The effect of cations on  $[^3\text{H}]\text{-LTB}_4$  binding. Lung membranes were incubated with  $[^3\text{H}]\text{-LTB}_4$  (1nM), at  $25^\circ\text{C}$  for 30 minutes. The divalent cations  $\text{Mn}^{2+}$  ( $\Delta$ ),  $\text{Mg}^{2+}$  ( $\square$ ), and  $\text{Ca}^{2+}$  ( $\bullet$ ) were used in part A. The monovalent cations  $\text{Na}^+$  ( $\bullet$ ),  $\text{K}^+$  ( $\circ$ ), and  $\text{Li}^+$  ( $\Delta$ ) were used in part B. Results are expressed as a percentage of control specific binding ( $153.0 \pm 4.7$  fmoles/mg). Points are the means of duplicate assays and are representative of at least 2 experiments.

reduced binding by 80%. These results are reminiscent of previous studies demonstrating similar effects of divalent and monovalent cations on the binding of  $\text{LTD}_4$  to guinea pig lung (15-17).

In competition assays (figure 3), we found that  $\text{LTB}_4$  and its hydroxy derivative  $20\text{-OH-LTB}_4$  were the most potent inhibitors of the binding of  $[^3\text{H}]\text{-LTB}_4$  to lung membranes. The rank order of potency for inhibition of binding was  $\text{LTB}_4 > 20\text{-OH-LTB}_4 \gg 20\text{-COOH-LTB}_4 = 6\text{-trans-12-epi-LTB}_4 > \text{LTC}_4 = \text{LTD}_4 = 5\text{-HETE}$ . Thus, the receptor we studied seems to be specific for  $\text{LTB}_4$  as  $\text{LTC}_4$  and  $\text{LTD}_4$  failed to compete for this binding site. The receptor also seems to have stereoselectivity since the stereoisomer of  $\text{LTB}_4$ ,  $6\text{-trans-12-epi-LTB}_4$  was significantly less potent than  $\text{LTB}_4$  in displacing  $[^3\text{H}]\text{-LTB}_4$  from its binding sites. The relative potency of  $\text{LTB}_4 > 20\text{-OH-LTB}_4 \gg 20\text{-COOH-LTB}_4$  in competing for the lung  $\text{LTB}_4$  binding site is the same as that observed in




Figure 3. Competition for  $[^3\text{H}]\text{-LTB}_4$  binding by lipoxigenase products. Lung membranes (0.4 mg/ml) were incubated with  $[^3\text{H}]\text{-LTB}_4$  (0.76 nM) in the presence of  $\text{Ca}^{2+}$  (10 mM) at  $25^\circ\text{C}$  for 30 minutes. Unlabelled competing ligands were  $\text{LTB}_4$  (●), 20-OH- $\text{LTB}_4$  (○), 20-COOH- $\text{LTB}_4$  (Δ),  $\text{LTC}_4$  (□),  $\text{LTD}_4$  (■), 5-HETE (▲), and 6-trans-12-epi- $\text{LTB}_4$  (▽). Points are means of duplicates expressed as a percentage of control binding ( $158.5 \pm 3.2$  fmoles/mg) and representative of 3 other experiments.

Figure 4. The effect of guanine nucleotides on  $[^3\text{H}]\text{-LTB}_4$  binding. Lung membranes (0.3 mg/ml) were incubated with  $[^3\text{H}]\text{-LTB}_4$  (0.76 nM) in the absence of any added cations. GTP (●),  $\text{GTP}\gamma\text{S}$  (○), and  $\text{Gpp}(\text{NH})\text{p}$  (□) were present in increasing concentrations in duplicate tubes. Binding was carried out at  $25^\circ\text{C}$  for 30 minutes. Volumes are expressed as a percentage of control total binding ( $166.3 \pm 16.1$  fmoles/mg).

competition experiments in human neutrophils (13) and in contractility studies on guinea pig lung parenchymal strips (27).

Guanine nucleotides GTP,  $\text{GTP}\gamma\text{S}$  and  $\text{Gpp}(\text{NH})\text{p}$  regulate the  $\text{LTD}_4$  receptor (15) and in our experiments the binding capacity of  $[^3\text{H}]\text{-LTB}_4$  to lung membranes was depressed in their presence (figure 4). The nonhydrolysable analog  $\text{GTP}\gamma\text{S}$  was the most potent with GTP being the least potent. The regulation of  $\text{LTB}_4$  binding by guanine nucleotides and cations suggests that this receptor may be linked to guanine nucleotide binding (N) proteins (15-17, 21-22). Originally it was thought that the N protein might be  $\text{Ni}$ , the inhibitory regulatory protein of adenylate cyclase, since  $\text{LTB}_4$  stimulated responses were blocked by pertussis toxin. However in light of recent findings that other

pertussis toxin substrate proteins exist in stimulated cells (23, 24) the identity of the LTB<sub>4</sub> regulating N proteins remains an open question. There is also evidence LTB<sub>4</sub> may generate second messengers via different pathways. For example, Holian showed that pertussis toxin blocks LTB<sub>4</sub> stimulated superoxide production and phosphatidyl turnover in guinea pig alveolar macrophages (25). However, Volpi et al (26) demonstrated that in rabbit neutrophils, LTB<sub>4</sub> mobilizes Ca<sup>2+</sup> without influencing polyphosphoinositide production. Further work is needed to clarify these aspects.

#### ACKNOWLEDGMENTS

Supported by AHFMR, The Arthritis Society, and the Alberta Lung Association. We thank A. Kiefer for her secretarial assistance.

#### REFERENCES

1. Borgeat, P., Hamberg, M., Samuelsson, B. (1976) *J. Biol. Chem.* 251, 7816-7820.
2. Ford-Hutchinson, A. W., Bray, M. A., Doig, M.V., Shipley, M. E., Smith, M.J.H. (1980) *Nature* 286, 264-265.
3. Bray, M.A., Ford-Hutchinson, A.W., Smith, M.J.H. (1981) *SRS-A and Leukotrienes*, pp 253, John Wiley and Sons, Ltd., Eng.
4. Borgeat, P., Samuelsson, B. (1979) *Proc. Natl. Acad. Sci. USA*, 76, 2148-2152.
5. Westcott, J.Y., Stenmark, K.R., Murphy, R.C. (1986) *Prostaglandins* 31, 227-237.
6. Salari, H., Borgeat, P., Braquet, P., Sirois, P., Morris, H.R., Taylor, G.W., Piper, P.J., Tippins, J.R. (1980) *Nature* 285, 104-106.
7. Turner, S.R., Campbell, R.A., Lynn, W.A. (1975) *J. Exp. Med.* 141, 1437-1442.
8. Goetzl, E.J., Pickett, W.C. (1980) *J. Immunol.* 125, 1789-1793.
9. Ford-Hutchinson, A.W., Bray, M.A., Shipley, M.E., Doig, M.V., Smith, J.J.H., (1980) *Int. J. Immunopharmacol.* 2, 232.
10. Moliski, T.F.P., Naccache, P.H., Borgeat, P., Sha'afi, R.I. (1981) *Biochem. Biophys. Res. Commun.* 103, 227-232.
11. Sirois, P., Roy, S., Tetrault, J.P., Borgeat, P., Picard, S., Corey, E.J. (1981) *Prostaglandins, Leukotrienes and Med.* 7, 327-340.
12. Goldman, D.W., Goetzl, E.J. (1982) *J. Immunol.* 129, 1600-1604.
13. Lin, A.H., Ruppel, P.L., Gorman, R.R. (1986) *Prostaglandins* 28, 837-849.
14. O'Flaherty, J., Kosfeld, S., Nishihira, J. (1986) *J. Cell. Physiol.* 126, 359-370.
15. Pong, S. DeHaven, R.N. (1983) *Proc. Natl. Acad. Sci. USA* 80, 7415-7419.
16. Lewis, M.A., Mong, S., Vessella, R.L., Hogaboom, G.K., Wu, H., Crooke, S.T. (1984) *Prostaglandins* 27, 961-973.
17. Bruns, R.F., Thomsen, W.J., Pugsley, T.A. (1983) *Life Sci.* 33, 645-653.
18. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J. (1951) *J. Biol. Chem.* 193, 265-275.
19. Harper, W.T., Westcott, J.Y., Voelkel, N., Murphy, R.C. (1984) *J. Biol. Chem.* 259, 14437-14440.
20. Sirois, P., Brousseau, Y., Chagnon, M., Gentile, J., Gladu, M., Salari, H., Borgeat, P. (1985) *Exp. Lung Res.* 9, 17-30.

21. Berridge, M.J., Irvine, R.F. (1984) *Nature* 312, 315-321.
22. Cockcroft, S., Comperts, B.D. (1985) *Nature* 314 534-536.
23. Gierschik, P., Falloon, J., Milligan, G., Pines, M., Gallin, J., Spiegel, A. (1986) *J. Biol. Chem.* 261, 8058-8062.
24. Milligan, G., Gierschik, P., Spiegel, A.M., Klee, W.A. (1986) *FEBS Lett.* 195, 225-230.
25. Holian, A. (1986) *FEBS Lett.* 201, 15-19.
26. Volpi, M., Yassin, R., Tao, W., Molski, T.F.P., Naccache, P.H., Sha'afi, R.I. (1984) *Proc. Natl. Acad. Sci. USA* 81, 5966-5969.
27. Hansson, G., Lindgren, J., Dahlen, S., Hedquist, P., Samuelsson, B. (1981) *FEBS Letts.* 130, 107-112.